Halozyme Therapeutics has finished investigating how glass particles ended up in some vials of Hylenex, a fluid-absorption drug recalled by manufacturing partner Baxter International in May. The investigation found that the drug and the glass vial were incompatible. The companies are preparing to present their corrective action and relaunch strategy to the FDA.

Related Summaries